Marina Biotech Enters Agreement with Autotelic Bio

Marina Biotech Enters Agreement with Autotelic Bio

Marina Biotech has entered into a binding license agreement with Autotelic Bio for the exclusive development and marketing outside of the United States and Canada of Marina's IT-103 clinical program. Under the agreement, Autotelic Bio will obtain a perpetual license to have the right and responsibility to begin clinical development of IT-103 for marketing approval in South Korea and territories outside of United States and Canada.

from Biotech News